作者: David G. Lambert
DOI: 10.1038/NRD2572
关键词:
摘要: Identification of the enigmatic nociceptin/orphanin FQ peptide (N/OFQ) in 1995 represented first successful use reverse pharmacology and led to deorphanization N/OFQ receptor (NOP). Subsequently, N/OFQ-NOP system has been implicated a wide range biological functions, including pain, drug abuse, cardiovascular control immunity. Although this could be considered hurdle for development pharmaceuticals selective specific disease indication, NOP represents viable target. This article describes potential clinical indications highlights current status very limited number trials.